{"id":"https://openalex.org/W31749136","doi":"https://doi.org/10.3233/jad-2008-14304","title":"Predictors of Placebo Group Decline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in 24 Week Clinical Trials of Alzheimer's Disease","display_name":"Predictors of Placebo Group Decline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in 24 Week Clinical Trials of Alzheimer's Disease","alternate_titles":[],"publication_year":2008,"publication_date":"2008-06-11","ids":{"openalex":"https://openalex.org/W31749136","doi":"https://doi.org/10.3233/jad-2008-14304","mag":"31749136","pmid":"https://pubmed.ncbi.nlm.nih.gov/18599956"},"language":"en","primary_location":{"id":"doi:10.3233/jad-2008-14304","doi":"https://doi.org/10.3233/jad-2008-14304","is_oa":false,"landing_page_url":"https://doi.org/10.3233/jad-2008-14304","pdf_url":null,"source":{"id":"https://openalex.org/S25155249","display_name":"Journal of Alzheimer s Disease","issn_l":"1387-2877","issn":["1387-2877","1875-8908"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318577","host_organization_name":"IOS Press","host_organization_lineage":["https://openalex.org/P4310318577"],"host_organization_lineage_names":["IOS Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's Disease","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W31749136"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109159919","display_name":"Michael C. Irizarry","orcid":"https://orcid.org/0000-0002-0246-2511","observed_orcids":["https://orcid.org/0000-0002-0246-2511"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael C. Irizarry","raw_affiliation_strings":["WW Epidemiology, GlaxoSmithKline, Harlow, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"WW Epidemiology, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David J. Webb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David J. Webb","raw_affiliation_strings":["Research Triangle Park, NC, US","WW Epidemiology, GlaxoSmithKline, Harlow, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]},{"raw_affiliation_string":"WW Epidemiology, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109962819","display_name":"Chanchal Bains","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chanchal Bains","raw_affiliation_strings":["Research Triangle Park, NC, US","WW Epidemiology, GlaxoSmithKline, Harlow, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]},{"raw_affiliation_string":"WW Epidemiology, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063854724","display_name":"Steven J. Barrett","orcid":"https://orcid.org/0000-0002-3570-3131","observed_orcids":["https://orcid.org/0000-0002-3570-3131"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Steven J. Barrett","raw_affiliation_strings":["Discovery Analytics, GlaxoSmithKline, Harlow, UK","Research Triangle Park, NC, US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Analytics, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113065527","display_name":"Robert Y. K. Lai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert Y. Lai","raw_affiliation_strings":["Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, UK","Research Triangle Park, NC, US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066572516","display_name":"Janette P. Laroche","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Janette P. Laroche","raw_affiliation_strings":["Neurosciences Medicine Development, GlaxoSmithKline, Harlow, UK","Research Triangle Park, NC, US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurosciences Medicine Development, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111880986","display_name":"David A. Hosford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David Hosford","raw_affiliation_strings":["Neurosciences Medicine Development, GlaxoSmithKline, Harlow, UK","Research Triangle Park, NC, US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurosciences Medicine Development, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027736490","display_name":"Gareth Maher\u2010Edwards","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gareth Maher-Edwards","raw_affiliation_strings":["Neurosciences Medicine Development, GlaxoSmithKline, Harlow, UK","Research Triangle Park, NC, US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurosciences Medicine Development, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112172198","display_name":"J Weil","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John G. Weil","raw_affiliation_strings":["Research Triangle Park, NC, US","WW Epidemiology, GlaxoSmithKline, Harlow, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Triangle Park, NC, US","institution_ids":[]},{"raw_affiliation_string":"WW Epidemiology, GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I188950975"],"apc_list":null,"apc_paid":null,"fwci":1.8555,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":{"value":0.83020626,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":97},"biblio":{"volume":"14","issue":"3","first_page":"301","last_page":"311"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.013199999928474426,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12848","display_name":"Psychological Testing and Assessment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3202","display_name":"Applied Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9559999704360962},{"id":"https://openalex.org/keywords/placebo-response","display_name":"placebo response","score":0.6110000014305115}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7299593091011047},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.6728184819221497},{"id":"https://openalex.org/C2984863031","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Cognitive decline","level":4,"score":0.6672243475914001},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6075092554092407},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.5900059342384338},{"id":"https://openalex.org/C4661277","wikidata":"https://www.wikidata.org/wiki/Q1054157","display_name":"Cog","level":2,"score":0.527600109577179},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5079205632209778},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.4953869581222534},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.45034876465797424},{"id":"https://openalex.org/C6057870","wikidata":"https://www.wikidata.org/wiki/Q5141248","display_name":"Cognitive test","level":3,"score":0.44335421919822693},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.38008683919906616},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36848294734954834},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.29750221967697144},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09477588534355164},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077154","descriptor_name":"Rosiglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009483","descriptor_name":"Neuropsychological Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014665","descriptor_name":"Vasodilator Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3233/jad-2008-14304","doi":"https://doi.org/10.3233/jad-2008-14304","is_oa":false,"landing_page_url":"https://doi.org/10.3233/jad-2008-14304","pdf_url":null,"source":{"id":"https://openalex.org/S25155249","display_name":"Journal of Alzheimer s Disease","issn_l":"1387-2877","issn":["1387-2877","1875-8908"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318577","host_organization_name":"IOS Press","host_organization_lineage":["https://openalex.org/P4310318577"],"host_organization_lineage_names":["IOS Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's Disease","raw_type":"journal-article"},{"id":"pmid:18599956","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18599956","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's disease : JAD","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320322546","display_name":"Shire","ror":"https://ror.org/02hb3t423"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1986144616","https://openalex.org/W2007164886","https://openalex.org/W2141108211","https://openalex.org/W2279154019","https://openalex.org/W2052939190","https://openalex.org/W2028881255","https://openalex.org/W2038555561","https://openalex.org/W2157417040","https://openalex.org/W2563929827"],"abstract_inverted_index":{"One":[0],"limitation":[1],"of":[2,15,43,56,85,147,161,170],"several":[3],"recent":[4],"24":[5,64,87,122,135],"week":[6,65,88,123],"Alzheimer's":[7],"disease":[8],"(AD)":[9],"clinical":[10,46,175],"trials":[11,47,176],"was":[12,117,127],"the":[13,20,27,40,54,63,75,81,86,121,157],"lack":[14,169],"cognitive":[16,70,132,183],"decline":[17,133,172,184],"detected":[18],"by":[19],"AD":[21,45,163,174,187],"Assessment":[22],"Scale-cognitive":[23],"subscale":[24],"(ADAS-cog)":[25],"in":[26,39,67,78,90,98,111,153,166,173,185,194],"placebo":[28,41,158,171],"groups,":[29],"possibly":[30],"obscuring":[31],"true":[32],"medication":[33],"effects.":[34],"Data":[35],"from":[36,113,141],"733":[37],"individuals":[38,138],"arms":[42],"six":[44],"performed":[48,165],"1996-1997":[49],"were":[50,80],"pooled":[51],"to":[52,115,130,143,156,182,190],"examine":[53],"relationship":[55],"clinical,":[57],"demographic,":[58],"and":[59,71,74,150,188],"genetic":[60],"characteristics":[61],"with":[62,100,120],"change":[66,77,89,110,124,152],"ADAS-cog.":[68,91],"Baseline":[69],"functional":[72],"status":[73],"screening-to-baseline":[76,151],"ADAS-cog":[79,93,112,154],"strongest":[82],"independent":[83],"predictors":[84],"The":[92,109,145],"did":[94],"not":[95],"detect":[96,131],"progression":[97],"patients":[99],"mild":[101,186],"dementia":[102],"(screening":[103],"Mini-Mental":[104],"State":[105],"Exam,":[106],"MMSE,":[107],">or=20).":[108],"screening":[114,142],"baseline":[116,148],"inversely":[118],"correlated":[119],"score;":[125],"it":[126],"more":[128,180],"difficult":[129],"at":[134],"weeks":[136],"if":[137],"markedly":[139],"worsened":[140],"baseline.":[144],"effects":[146],"MMSE":[149],"generalized":[155],"group":[159],"(N=106)":[160],"another":[162],"study":[164],"2004-2005.":[167],"Overcoming":[168],"will":[177],"require":[178],"scales":[179],"sensitive":[181],"strategies":[189],"reduce":[191],"within-person":[192],"variability":[193],"outcome":[195],"measures.":[196]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W31749136","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-15T12:55:33.944570","created_date":"2016-06-24T00:00:00"}
